Citadel Advisors’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-20,100
Closed -$4.23K 15486
2023
Q2
$4.23K Hold
20,100
﹤0.01% 13616
2023
Q1
$3.22K Buy
+20,100
New +$8.93K ﹤0.01% 14060
2022
Q1
Sell
-19,100
Closed -$43K 14962
2021
Q4
$43K Sell
19,100
-9,200
-33% -$23.1K ﹤0.01% 13329
2021
Q3
$97K Buy
28,300
+5,500
+24% +$17K ﹤0.01% 12919
2021
Q2
$68K Sell
22,800
-5,600
-20% -$17.7K ﹤0.01% 13184
2021
Q1
$92K Buy
28,400
+16,200
+133% +$54K ﹤0.01% 12544
2020
Q4
$26K Buy
+12,200
New +$20.1K ﹤0.01% 10739
2018
Q3
Sell
-13,000
Closed -$25K 9846
2018
Q2
$25K Buy
13,000
+2,200
+20% +$4.45K ﹤0.01% 8600
2018
Q1
$23K Buy
+10,800
New +$23.2K ﹤0.01% 8103
2017
Q1
Sell
-16,300
Closed -$22K 8198
2016
Q4
$22K Buy
+16,300
New +$21.3K ﹤0.01% 7061
2015
Q4
Sell
-2,400
Closed -$20K 9343
2015
Q3
$20K Sell
2,400
-1,100
-31% -$10.1K ﹤0.01% 8156
2015
Q2
$38K Sell
3,500
-15,600
-82% -$200K ﹤0.01% 7842
2015
Q1
$267K Buy
19,100
+5,100
+36% +$78K ﹤0.01% 5822
2014
Q4
$236K Sell
14,000
-4,700
-25% -$68.4K ﹤0.01% 5777
2014
Q3
$251K Buy
18,700
+16,200
+648% +$193K ﹤0.01% 5474
2014
Q2
$32K Sell
2,500
-600
-19% -$6.25K ﹤0.01% 7046
2014
Q1
$37K Sell
3,100
-4,400
-59% -$59K ﹤0.01% 6966
2013
Q4
$104K Sell
7,500
-16,100
-68% -$227K ﹤0.01% 5576
2013
Q3
$412K Sell
23,600
-48,800
-67% -$935K ﹤0.01% 4019
2013
Q2
$1.18M Buy
+72,400
New +$2.24M ﹤0.01% 3024

Other funds holding INFI

Citadel Advisors's INFI Position: Q2 2023 in Review

Citadel Advisors sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q2 2023, closing a stake of 393,296 shares — an estimated $68.3K sold.

Citadel Advisors first reported a position in INFI in Q2 2013 and held it in 28 quarters. The position peaked at $7.57M in Q4 2014. 45 funds tracked by Wall St. Rank hold INFI as of Q2 2023.

  • Citadel Advisors reported no remaining Infinity Pharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
  • Citadel Advisors sold 393,296 Infinity Pharmaceuticals, Inc. shares in Q2 2023, an estimated $68.3K.
  • Citadel Advisors first reported a position in Infinity Pharmaceuticals, Inc. in Q2 2013 and held it in 28 quarters.
  • Citadel Advisors's Infinity Pharmaceuticals, Inc. position peaked at $7.57M in Q4 2014.
  • 45 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q2 2023.

Based on Citadel Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.